Glyphic Biotechnologies
Glyphic Biotechnologies is developing a single-molecule, massively parallel protein sequencing platform that does not rely on the existing, decades-old technologies of ELISA and mass spectrometry. This platform will enable the sequencing of billions of proteins simultaneously to enable novel applications in human health, industrial biotechnology, and biopharma discovery.
Company Ownership:
Socially Disadvantaged
Contact Name:
Joshua Yang
Contact Email:
Website:
https://glyphic.bio/
City, State – Congressional District:
New York,
NY
–
12
Technology:
Drug
Funding:
Genome (NHGRI)
NIH Projects:
NIH RePorter for
Glyphic Biotechnologies
Sponsored Event(s):
RESI/LifeScience Nation | 2023
